Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

M. Strauss, Gary; E. Herndon, James; A. Maddaus, Michael; W. Johnstone, David; A. Johnson, Elizabeth; Watson, Dorothy; J. Sugarbaker, David; L. Schilsky, Richard; R. Green, M.

doi:10.1200/jco.2004.22.14_suppl.7019

Public

Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

Published in Journal of Clinical Oncology • Jul 15, 2004

Authors:

Gary M. Strauss

James E. Herndon

Michael A. Maddaus

Abstract

7019 Background: The value of adjuvant chemotherapy in resectable lung cancer remains controversial. The International Adjuvant Lung Trial (IALT) reported a modest but statistically significant survival advantage with cisplatin-based adjuvant chemotherapy in stages IA to III NSCLC. On the other hand...

Subject

Medicine

Carboplatin

Lung cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!